/
DCF Valuation
Base-case fair value
$134.72
Intrinsic $179.63 · 25% MOS
Current price: $16.58
Base-case summary
Our base-case DCF for Theravance Biopharma, Inc. (TBPH) projects 10 years of free cash flow growth at 12.7% for years 1–5 and 6.4% for years 6–10, anchored to 12.7% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $269M in trailing free cash flow, this produces an intrinsic value of $179.63 per share. A 25% safety margin gives a fair value of $134.72, suggesting the stock is currently 713% undervalued against the $16.58 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$269M
Cash & equivalents
$395M
Total debt
$41M
Shares outstanding
51M